Mosaic ImmunoEngineering Inc.

Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company focused on advancing and commercializing immunotherapies for cancer treatment. The company has historically developed early-stage product candidates and is now pursuing new product candidates and platforms to build a product pipeline, leveraging its understanding of immunotherapies. Its business strategy involves using industry experience, immunotherapy knowledge, and development expertise to identify, develop, and commercialize product candidates that address unmet medical needs in cancer treatment and have significant market potential. The company has a management team and scientific and business advisors, including experts in immunotherapy, with industry and regulatory experience to lead product development and commercialization. Mosaic ImmunoEngineering Inc. is focused on identifying and licensing or acquiring new product candidates. As part of this strategy, on April 26, 2024, the company entered into a binding term sheet with Oncotelic Therapeutics, Inc. to acquire certain rights to Oncotelic's clinical-stage necroptosis cancer therapies associated with its vascular disruptive agents and related regulatory and clinical packages. It also intends to acquire non-exclusive access to Oncotelic's proprietary Artificial Intelligence technologies for identifying immunotherapy combinations. This acquisition is in exchange for shares of Mosaic ImmunoEngineering Inc. common stock valued at $15.0 million upon execution of the definitive agreement, or a combination of common stock and preferred stock. Additionally, Oncotelic can earn up to an additional $15.0 million in shares of common stock, valued at the time of issuance, if specific milestones are met.